Medicine and Dentistry
Neoplasm
100%
BRCA1
63%
Immune Checkpoint Inhibitor
55%
Overall Survival
46%
Ovarian Cancer
46%
Malignant Neoplasm
45%
Serous Carcinoma
44%
Targeted Therapy
43%
Organoid
42%
Diseases
39%
Side Effect
39%
Recurrent Disease
38%
Endometrial Cancer
37%
Salpingooophorectomy
37%
Disease
36%
T Cell
36%
Quality of Life
35%
Cohort Analysis
33%
Nodular Melanoma
29%
Kidney Graft
28%
Xerostomia
28%
Germ Cell
28%
Carcinoma in Situ
28%
Radiation Therapy
27%
Proton Therapy
27%
Radiation Therapy
26%
Progenitor Cell
25%
Salivary Gland
25%
B Cell
25%
Uterine Cancer
24%
Chemoradiotherapy
22%
Immunotherapy
22%
Recurrence Risk
22%
Arm
21%
Systemic Therapy
20%
Oncologist
20%
Melanoma
20%
Stem Cell
19%
Krukenberg Tumor
19%
Immune Response
19%
Lung
18%
DNA Mismatch Repair
18%
Granulosa Cell Tumour
18%
Immune Disorder
18%
Cancer Research
18%
Vulvar Cancer
18%
Classical Hodgkin Lymphoma
18%
Radiation Oncology
18%
Diffuse Large B-Cell Lymphoma
18%
In Vitro
18%
Molecularly Targeted Therapy
18%
Parotid Gland
18%
Medicine
17%
Cancer Cell
17%
Cancer Registry
17%
Neoadjuvant Chemotherapy
17%
Progression Free Survival
16%
Cancer Therapy
16%
Submandibular Gland
16%
Biopsy
16%
Primary Central Nervous System Lymphoma
16%
Hazard Ratio
16%
Dendritic Cell
15%
Drug Megadose
15%
Adjuvant Therapy
15%
Autologous Stem Cell Transplantation
15%
Clinical Trial
14%
Stem Cell
14%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
14%
Epithelial Cell Adhesion Molecule
14%
Positron Emission Tomography
13%
Disease Free Survival
13%
Protein P53
13%
Pembrolizumab
13%
Prospective Study
12%
Head and Neck Cancer
12%
Obstetrics
12%
Gynecology
12%
Cancer Immunotherapy
12%
Esophageal Cancer
12%
Ipilimumab
12%
Personalized Medicine
11%
Cell Therapy
11%
Serositis
11%
Infection
11%
Magnetic Resonance Imaging
11%
Cell Function
11%
Long Term Survival
11%
Signal Transduction
11%
Heart Right Ventricle Function
11%
Squamous Cell Carcinoma
11%
Immunity
10%
Microglia
10%
Combination Chemotherapy
10%
Tumor Infiltrating Lymphocyte
10%
Nivolumab
10%
Cytotoxicity
10%
Diagnosis
10%
PARP Inhibitor
10%
Diagnostic Accuracy
10%
Keyphrases
Immune Checkpoint Inhibitors
61%
BRCA1, BRCA2
47%
Tumor
47%
Radiotherapy
46%
Endometrial Cancer
42%
Esophageal Cancer
37%
High-grade Serous Carcinoma
37%
Risk-reducing Salpingo-oophorectomy
37%
Targeted Therapy
37%
Overall Survival
34%
Germline Pathogenic Variant
31%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
29%
Cancer Patients
28%
Netherlands
25%
Genomic Instability
22%
Ovarian Cancer
21%
Health-related Quality of Life
21%
Neoadjuvant
20%
Advanced Melanoma
20%
Survival Outcomes
20%
Progression-free Survival
19%
Kidney Transplant Recipients
18%
Mismatch Repair
18%
Large B-cell Lymphoma
18%
Diagnostic Accuracy
18%
Organoids
18%
Radiation-induced Xerostomia
18%
B Cells
18%
Mantle Cell Lymphoma
18%
Vulvar Cancer
18%
Pneumonia
18%
Oncologists
18%
Targeted Cancer Therapy
18%
Proton Radiotherapy
17%
Metabolic
16%
Neoadjuvant Chemoradiotherapy (nCRT)
16%
Salivary Gland
16%
Radiation Dose
15%
Dutch
14%
Complete Response
14%
High Risk
14%
Patient Well-being
14%
Vulvar Squamous Cell Carcinoma
13%
Cancer Registry
13%
Stem Progenitor Cells
13%
Disease-free Survival
13%
18F-FDG PET-CT
13%
Pembrolizumab
13%
Gross Tumor Volume
13%
Partial Response
13%
Ipilimumab
13%
Replication Stress
12%
Clinical Trials
12%
Obstetrics
12%
Biobank
12%
Cancer Cells
12%
Disease Pattern
12%
Oncological Treatment
12%
Clinical Grade
12%
Xerostomia
12%
Early Effect
12%
Mutational Profile
12%
Treatment Strategy
12%
Systemic Therapy
12%
Groningen
12%
Salivary Gland Organoids
12%
Patient Cohort
12%
Head-and-neck Cancer
11%
Tissue Sampling
11%
Axicabtagene Ciloleucel
11%
Cyclin E1
11%
Dose Effect
11%
R-CHOP
11%
Sigma Phase
11%
Melanoma
11%
Clinical Application
11%
Tumor Volume
11%
Normal Tissue Damage
11%
Oncological Outcomes
11%
Nivolumab
11%
Long-term Survival
11%
Salvage Chemotherapy
11%
Lymphoma Patients
11%
Prognostic Impact
10%
Autoimmunity
10%
Quality of Life
10%
Immune Checkpoint Inhibitor Treatment
10%
Breast Cancer Susceptibility Gene 1 (BRCA1)
10%
Lung
10%
Corticosteroids
10%
Chimeric Antigen Receptor T Cells (CAR-T)
10%
Cell Therapy
10%
Stem Cells
10%
Recurrence Risk
10%
Treatment Outcome
10%
High-grade Serous Ovarian Cancer (HGSOC)
10%
Chemotherapy
10%
Replication Speed
10%
Complete Remission
10%
P53 Abnormal
10%
Immunology and Microbiology
B Cell
68%
Overall Survival
38%
Immunotherapy
34%
Low Drug Dose
30%
T Cell
29%
Lymphoma Cell
28%
Tumor Cell
27%
Positron Emission Tomography
26%
Cycline
23%
Macrophage
21%
Dynamics
21%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
21%
Genomic Instability
19%
Mechanical Stress
18%
Monospecific Antibody
18%
Rheumatic Polymyalgia
18%
Germ Cell
18%
interferon
18%
Cancer Cell
17%
Immunity
16%
Atezolizumab
15%
Signal Transduction
15%
Disease Free Survival
15%
Organoid
14%
Cytotoxicity
13%
Inflammation Response
13%
Immunocompetent Cell
13%
DNA Replication
13%
Interleukin 6
12%
DNA Damage
12%
Autoimmunity
12%
Tumor-Infiltrating Lymphocytes
12%
Infrared Radiation
12%
Axicabtagene Ciloleucel
11%
Cytokine Release Syndrome
11%
Immune Response
11%
Cytokine
11%
Tumor Volume
11%
Blood Plasma
11%
Gene Expression Profiling
10%
Cetuximab
10%
Immune Cell Infiltration
10%
Oncogene C Myc
10%
Neck
10%
Tumor Necrosis Factor
10%
Cyclophosphamide
10%
Hematopoietic Cell
10%
Cancer Immunotherapy
10%
Inflammatory Disorder
10%
Tumor Immunity
10%
Gene Expression
10%
P53
9%
Enhancer Region
9%
Selenium Blood Level
9%
Metabolism
9%
Transplant Procedure
9%
Enzyme Active Site
9%
MYD88
9%
Cell Phagocytosis
9%
Droplet Digital Polymerase Chain Reaction
9%
Memory T Cell
9%
Immunoglobulin Heavy Chain
9%
Transcriptomics
9%
Memory B Cell
9%
Clustered Regularly Interspaced Short Palindromic Repeat
9%
Bursitis
9%
Chimeric Antigen Receptor T-Cell
9%
Mismatch Repair
9%
Gene Interaction
9%
Skinfold
9%
Fiber Optics
9%
Radiation Field
9%
Mitophagy
9%
CD20
9%
Conformation
9%
Time Factor
9%
Trastuzumab
9%
Granulocyte Macrophage Colony-Stimulating Factor
9%
Mouth Mucosa
9%
Fibroblast
9%
Gross Tumor Volume
9%
Cancer Tissue
9%
Cells by Function
9%
Stem Cell Factor
9%
Cortisol
9%
Salivary Gland
9%
Viral Disease
9%
Leporidae
9%
Chromatin Assembly and Disassembly
9%
Immune Disorder
9%
Brain Cell
9%
Pemphigus vulgaris
9%
Interleukin 17
9%
Peptidoglycan
9%
Calorie
9%
Disease Burden
9%
Immune System Disorders
9%
Brain Region
9%
CD40 Ligand
9%
Lifespan
9%